Ultragenyx Pharmaceutical Inc. (RARE) Misses Q2 EPS by 3c

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical Inc. (RARE) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
• Hyperscale Data launches $300M at-the-market stock offering